Presenting Partner

Life Insurance Corporation of India

Moneycontrol

Budget 2022

Associate Partners:

  • Kotak Mutual Fund
  • Pharmeasy
  • Indiabulls
  • State Bank of India
  • CoinSwitch Kuber

Presenting Partner

Life Insurance Corporation of India

Moneycontrol

Budget 2022

Technology Partner

Dell Technologies

Associate Partners

Kotak Mutual Fund
Pharmeasy
Indiabulls
State Bank of India
CoinSwitch Kuber
you are here:

Lyka Labs Ltd.

BSE: 500259 | NSE: LYKALABS |

Shares falling in the `Trade-to-Trade` or `T-segment` are traded in this series and no intraday is allowed. This means trades can only be settled by accepting or giving the delivery of shares.
Series: BE | ISIN: INE933A01014 | SECTOR: Pharmaceuticals

BSE Live

Jan 28, 16:00
181.25 -9.50 (-4.98%)
Volume
AVERAGE VOLUME
5-Day
2,527
10-Day
15,970
30-Day
77,353
1,387
  • Prev. Close

    190.75

  • Open Price

    181.25

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    181.25 (137713)

NSE Live

Jan 28, 15:54
180.85 -9.50 (-4.99%)
Volume
AVERAGE VOLUME
5-Day
18,616
10-Day
96,356
30-Day
375,848
25,911
  • Prev. Close

    190.35

  • Open Price

    180.85

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    180.85 (116675)

Company History - Lyka Labs
YEAR                       EVENTS
 1976 - The company was incorporated on 29th December as a private
        Limited Company and Converted into a Public Limited company
 on
        19th December, 1985.
 
      - The company alongwith Gujarat Industrial Investment
 Corporation
        Limited promoted a new company, Gujarat Lyka Organics Limited,
 at
        Ankleshwar in Gujarat for the manufacture of Semi-Synthetic
        Penicilline.
 
 1993 - The Company proposed to offer 20,60,000 No. of Equity Shares
 of
        Rs. 10/- each at an issue  price not exceeding Rs. 35/- per
 share
        on the basis of one Equity Share for every two Equity Shares.
 
 1994 - The company is negtiating tieup arrangements with
 internationally
        reputed manufactureres for marketing and manufacturing its
        products in India.
 
 1995 - Government of India has selected the Company for the award of
 the
        Certificate of Merit for the excellent export performance
 during
        1993-94.  Further CHEMEXCIL has also selected the Company for
 the
        SECOND AWARD for outstanding export performance during
 1993-94.
 
      - The Company has commenced production at its new formulation
 plant
        at Tarapur, have been designed with state-of-the-art
 technology
        to meet with the International Standards of Good
 Manufacturing
        Practices and with Total Quality Management Systems (TOM).  
 
      - The Company has also set up additional manufacturing facility
 for
        ointment at Ankleshwar 
 
      - Lyka Exports Limited became a subsidiary of the Company.
 
      - The Company allotted 1,50,000 Equity Shares to Foreign
        Institutional Investors on private placement basis and 40,000
        Equity Shares to the Promoters.
 
 1997 - The Company during the period has allotted 5,65,000 Secured
        Redeemable Non-Convertible Debentures of Rs.100/- each
        aggregating to Rs.5.65 crores.
 
      - Lyka Labs Limited has entered into the marketing of skin
 cream
        which is used to treat dry skin conditions.
 
      - The company has recently launched a rubefacient, too.
 
 1998 - The Company's Administrative Office and Corporate Quality
        Assurance at Mumbai and Plant at Tarapur has been awarded ISO
        9002 Certification for its Quality Management System by SGS
        Yarsley International Certification Services Limited, U.K.
 
 1999 - Lyka Labs has launched a product-rationalisation exercise to
        exit cardiovasculars which is a non-focus area, sources opine.
 
 
      - The company recently launched dermatological skin ointment
        Cetraben.
 
 2000 - The Company to issue on preferential basis 30,00,000 No. of
        equity shares of Rs. 10/- each on preferential allotment to
        Financial Institutions/FIIs/MFs.
 
 2003
 -Entered into an agreement with BDR Pharmaceuticals International to
 form a 50:50 joint venture. The new company will be focussed on
 enhancing Lyka's export business to developed and developing
 countries, which at present being handled by Lyka. 
 
 -Lyka Labs marketing tie-up with Bio X-Healthcare
 
 -Lyka Labs Ltd has informed that the Company has decided to
 dis-invest its holding in its subsidary, Lyka Exports Ltd. In view of
 this, Lyka Exports Ltd. will cease to be its subsidary.
 
 2005
 
 -Lyka Labs launches BIOXTRA Toothpaste & Gel
 
 -Clearwater Capital Partners Limited joined hands with Lyka Labs Ltd
 
 2006
 
 -Lyka Labs Ltd has informed that Lyka Labs Ltd has changed the
 Registrar and Transfer Agent from MCS Ltd to Sharex Dynamic ( India )
 Limited, Unit No.1, Luthra Ind. Premises, Andheri Kurla Road, Safed
 Pool, Andheri ( East ) Mumbai 400 072, Tel No. 2851 5606/44 Fax 2851
 2885, with effect from September 30, 2006.
 
 2008
 
 -Lyka Labs Ltd has appointed Mr. D G Shah as Additional Director of
 the Company.
 
 2009
 
 - Lyka Labs Ltd has re-appointed Shri. N. I. Gandhi as Managing
 Director of the Company w.e.f. 1st April, 2009, subject to approval
 of the Central Government.
 
 2010
 
 - Lyka Labs Ltd has appointed Mr. Manish Jaywant as CFO w.e.f. June
 01, 2010.
 
 2011
 
 - The Company has been conferred Certificate of Appreciation Patent
 Award by Pharmaceuticals Export Promotion Council.
 
 - The Company has entered MOU with European based Company for
 Transfer Known- How / Technology to manufacture lyophilized product.
 
 2012
 
 - Email ID : investorredressal@lykalabs.com 
 
 
 2014
 
 -Mr. Yogesh B. Shah has been appointed as Chief Finance Officer.
 
 2016
 
 -Lyka Healthcare Limited, an entirely owned subsidiary of Lyka Labs
 Limited, has launched two domestic marketing divisions.